Clinical and Patient Reported Outcomes for Individuals With Relapsed/Refractory Multiple Myeloma Treated With Isatuximab: Real-World Insights From Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching
Latest Information Update: 28 May 2024
At a glance
- Drugs Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 23 May 2024 Planned End Date changed from 1 Dec 2023 to 31 Dec 2024.
- 23 May 2024 Planned primary completion date changed from 1 Aug 2023 to 31 Oct 2024.
- 11 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.